Vitiligo
Not recruitingStudy on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Belgium- Participants:18–64 years · 65+ years
- Substances:MK-6194
- Sponsor:Merck Sharp & Dohme LLC
Rare diseases
Investigational molecules
Locations
Back to Belgium1 426 clinical trials in Bouge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
BelgiumStudy of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment
BelgiumStudy Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer
BelgiumStudy on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older
BelgiumStudy on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II
BelgiumStudy on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis
BelgiumStudy of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
BelgiumStudy on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy
BelgiumStudy of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors
BelgiumStudy of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer
BelgiumStudy on Sibeprenlimab for Patients with IgA Nephropathy
BelgiumStudy on the Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Clinical investigations focusing on recurrent orofacial herpes infections aim to evaluate innovative therapeutic approaches. The research examines the effectiveness of new treatments in reducing episode frequency over a 12-month period.
Studies include controlled trials testing specialized medications for patients experiencing frequent outbreaks.
Research centered on managing functional dyspepsia and related gastrointestinal conditions explores optimal medication reduction strategies. The studies evaluate various approaches to discontinuing long-term proton pump inhibitor use.
Trials compare different therapeutic strategies, including on-demand medication use and alternative treatment formulations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.